Connect with us

NEWS

FDA Ties Zolgensma Tumors to a Cancer Gene Insertion

Zolgensma’s tumor cases are now a confirmed GLI1 insertion signal, and the FDA has folded Itvisma into the same probe.

Published

on

The FDA said on November 6 that Zolgensma gene therapy inserted its own DNA into a cancer gene, GLI1, in children who later developed tumors. Novartis had just told doctors it had 9 reports of tumors in treated patients, 2 of them with vector DNA sitting in the child’s genome. The agency still says the benefits of the spinal muscular atrophy infusion outweigh the risks. It also pulled a second Novartis product, Itvisma, into the same investigation because the two shots share a vector and a construct.

That is the part the 2019 label never had to carry. The warning then called tumor risk theoretical. It is no longer a theory on paper, and more than 6,000 children have already had the dose.

FDA Maps Zolgensma DNA Onto the GLI1 Oncogene

Zolgensma (onasemnogene abeparvovec-xioi) is an adeno-associated virus serotype 9 infusion for children under 2 with SMA and two faulty copies of SMN1. The vector is built to ferry a working SMN1 gene and then persist mostly as a free-floating loop of DNA, not as a permanent splice into chromosomes. Random insertion still happens, and the U.S. label has said so. Until this month it also said a causal link to tumors had not been established.

The FDA’s November 6 note changes that wording’s force. Postmarketing reports include tumors of the central and peripheral nervous systems, the spinal and paraspinal regions, and the kidney. Three of those tumors were tied to GLI1, an oncogene that can drive cancer when it is switched on too hard. In two cases, lab work on tumor tissue found Zolgensma vector DNA in the child’s genome, with the promoter of the treatment construct sitting upstream of or inside GLI1. The third GLI1 case is still being picked apart.

The Food and Drug Administration (FDA) has received postmarketing adverse event reports of malignancies in patients treated with Zolgensma, an adeno-associated virus (AAV) vector-based gene therapy, for spinal muscular atrophy (SMA), including confirmed reports of product-related insertional oncogenesis involving the GLI1 (Glioma-Associated Oncogene Homolog 1) gene.

U.S. Food and Drug Administration, November 6, 2026 safety communication

Novartis’s public line is narrower. The company said two cases “have shown evidence of vector DNA integration into the DNA of the patients,” that both children were treated for their tumors, and that both remain under monitoring. It also said it notified health authorities in each case. The FDA’s phrase is harder: confirmed reports of product-related insertional oncogenesis. That is the regulator calling the insertion a cause, not a coincidence, in those two children.

The current prescribing information still speaks of a “theoretical risk of tumorigenicity due to integration of AAV vector DNA into the genome.” The agency said it is moving quickly to test whether that language, and the long-term follow-up studies Novartis already runs, are enough.

Nine Reports, Two Integrations, Six Unsolved

Nine tumor reports among more than 6,000 treated patients is the company’s count since first approval on May 24, 2019, across trials, managed access, and commercial use. Two of those nine are the integration cases. Seven of the nine had not been public before neurologists started getting letters this month. Two earlier tumor reports in treated children had already shown up in the medical literature, which is why the new batch landed as a surprise.

A separate tally sits in the clinic notes. England’s National Multidisciplinary Team for Zolgensma, in a November 4 update posted by SMA UK, said pathology had been finished on 3 of the 9 tumors: 2 specifically related to treatment, 1 appearing unrelated. That leaves 6 reports without a completed tumor workup. The FDA’s three GLI1-associated tumors are a molecular series, not a second count of the same three slides, and the two lists should not be mashed into one.

THE NINE TUMOR REPORTS

What is known Count Who said it
Tumor reports since 2019 approval 9 Novartis
Vector DNA found in the tumor 2 Novartis
Pathology completed 3 of 9 UK MDT / Cure SMA
Called related after pathology 2 UK MDT / Cure SMA
Called unrelated after pathology 1 UK MDT / Cure SMA
Still without completed pathology 6 9 minus 3
GLI1-associated tumors 3 FDA
Patients treated worldwide More than 6,000 Novartis

Those 9 reports are spontaneous safety cases, not a finished registry, so they do not support a clean rate. The UK team told families the confirmed number is small next to more than 6,000 doses. Small is not the same as closed. Six files are still dark, and the two molecular matches already forced a federal investigation.

This is also not Zolgensma’s first label fight. In 2022 Novartis said two children had died of acute liver failure about five to six weeks after infusion, around the time steroids were being tapered. The boxed warning was tightened. Liver injury was the near-term risk doctors already watched. Tumors, if they track with insertion, show up later, which is why a one-time infant infusion can look finished in the chart and still be live in the genome.

Itvisma Carries the Same Vector Into Older Patients

Zolgensma is the intravenous product for children younger than 2. Itvisma (onasemnogene abeparvovec-brve) is the same gene, same AAV9 chassis, given as an intrathecal injection for people 2 and older. The FDA approved Itvisma on November 24, 2025. The European Commission followed on July 2, 2026, for a broad SMA group that includes teens and adults. No tumor has been reported after Itvisma. The agency said the neoplasia risk still applies because the vector and construct are the same.

That matters for the franchise, not only for the file. Novartis reports Zolgensma and Itvisma together as Zolgensma Group. In the first nine months of 2026 the group took in $1.071 billion, up 16 percent in dollars and 13 percent at constant currencies. Third-quarter sales were $404 million, up 34 percent in dollars and 35 percent at constant currencies. The company’s own third-quarter note tied that jump to launch momentum from Itvisma in the US, Japan, and other markets outside the United States.

The product lifting the line is the one the FDA just swept into a cancer investigation with zero Itvisma cases on the board. Older children, teens, and adults who were never eligible for the infant infusion now share a theoretical-to-confirmed insertion risk they did not have a year ago. Rival SMA drugs, Biogen’s Spinraza and Roche’s Evrysdi, are chronic treatments rather than one-time gene replacement. They do not use this vector. They also do not offer the single-infusion pitch Novartis priced at $2.125 million when Zolgensma launched in 2019.

FDA said it is watching similar AAV programs as a class. It is also weighing whether any regulatory step is warranted while repeating that, for the approved SMA uses, benefits still come out ahead of the new risk.

How Families Learned Before the Company Spoke

Parents of treated children heard from neurologists in early November, then from one another, before Novartis put a statement in public. Clinic visits around November 4 carried the same briefing: two tumors tied to the therapy, more reports still being sorted, information coming out in stages. A private Facebook note and a LinkedIn share by a hospice chaplain pushed the letters into the open. SMA Europe said it had been told through confidential channels. Cure SMA, in the United States, said the same day that it was reviewing available safety information with clinical experts and had reached out to the company.

THE DISCLOSURE WEEK

  1. November 4, 2026: England’s National Multidisciplinary Team for Zolgensma posts a safety update. Families in clinic describe a coordinated round of neurologist letters.
  2. November 5, 2026: SMA Europe and Cure SMA publish community notes. Novartis gives SMA Europe a statement counting 9 tumor reports and 2 integration cases.
  3. November 6, 2026: FDA posts its investigation of a serious malignancy risk, names GLI1, and extends the warning to Itvisma.

Novartis said patient safety is its priority and that health authorities were notified in a timely way in each case. That claim and the family timeline can both be true. Regulators can have the files while parents are still matching screenshots. SMA Europe’s ask was not a scientific debate. It was a public one.

Families need clear, reliable and understandable information and should not be left to piece together a potential safety concern from social media, rumours or incomplete reports.

SMA Europe, November 5, 2026 community statement

The group said it had told Novartis that the SMA community now needs timely public communication on what is known, what is not, what the news means for children already treated, and whether extra monitoring is warranted. The Muscular Dystrophy Association used the same week to say families deserve timely, science-based information. None of those groups told parents to abandon the drug. All of them said the drip of letters was the wrong way to learn that a one-time gene therapy had a new cancer file.

Long-term genomic checks after AAV can no longer be treated as a paperwork extra. The two molecular matches are in children who already received a marketed product, not in a paused trial. That is why the clinic letters landed so hard. There is no second appointment at which the vector comes out.

Krabbe and MPS Trials Show the Same Insertion Pattern

The FDA did not keep the finding inside Novartis. Its note cites two 2026 papers in the New England Journal of Medicine on AAV insertion driving tumors in other programs. Vo and colleagues described a GLI1 integration and a paraspinal tumor after Forge Biologics’ FBX-101 in infantile Krabbe disease; the child was still without symptoms at last follow-up. Ahrens-Nicklas and colleagues described a PLAG1 integration and a neuroepithelial tumor after Regenxbio’s RGX-111, delivered into the cisterna magna for MPS I in a 5-year-old boy. The tumor was removed. The authors wrote that rare AAV integration can contribute to human tumor formation and that transduced tissue needs watching after treatment.

Regenxbio’s RGX-111 program has been under an FDA clinical hold since January, and the agency also held a related MPS II candidate, RGX-121, on the same shared-risk logic. Those holds sat in trial-land. Zolgensma does not. It is a commercial infusion already given to more than 6,000 patients.

THREE AAV PROGRAMS, THREE INSERTIONS

Program Who makes it Insertion finding Where it stands
Zolgensma Novartis GLI1; promoter in or near the gene in 2 tumors Marketed; FDA investigating
FBX-101 Forge Biologics GLI1; paraspinal tumor Trial report, October 2026
RGX-111 Regenxbio PLAG1; neuroepithelial tumor Clinical hold since January 2026

GLI1 showing up in more than one AAV file is the detail that should bother vector labs. If insertion were pure noise, the same oncogene would be a coincidence. Two programs hitting GLI1 in the same year is a pattern the FDA is now willing to print. Cassette design, splice donors, and vector purity are the fixes the FBX-101 authors flagged. None of those fixes can be retrofitted into a child who was dosed in 2020.

The Dose Cannot Be Withdrawn

The live fight is not whether SMA gene therapy still saves infants who would otherwise lose motor neurons and, in the severe form, often die in early childhood. FDA has not pulled Zolgensma or Itvisma. The live fight is what to do with the children who already got the infusion, and whether “watch and wait” means the same thing in Bethesda and in London.

WHAT CLINICS ARE TELLING FAMILIES NOW

  • FDA: Patients and trial participants on Zolgensma or Itvisma should be monitored for tumor formation while the agency studies whether the label and follow-up studies are adequate.
  • UK MDT: Based on what is now known, it recommends no additional scans, tests or monitoring and no change to routine care, pending further word from regulators.
  • Novartis: The tumor risk is already on the Zolgensma label; doctors who see a tumor should call Novartis Gene Therapies at 1-833-828-3947.
  • Open file: Six of the nine reports still lack completed pathology, and the third GLI1 case has no settled mechanism.

Those are two different instructions on the same bodies. A family in England was told not to add scans. A U.S. safety note told clinicians to watch for tumors. Neither side has published the ages of the children, the tumor types beyond the FDA’s organ list, or how many years sat between the infusion and the diagnosis. One parent account described the confirmed cases as arriving years after dosing, which matches a risk that would not show up in the first month of steroid cover. That timing is still unofficial. The molecular work is not.

SMA Europe is collecting questions for Novartis. Cure SMA is doing the same with U.S. clinicians. The company has not released case narratives. Until the six unfinished files are closed and the label’s “theoretical” line is rewritten or defended, the people with the least room to move are the ones who already had the one-time dose. They cannot reverse an AAV insertion. They can only wait on the next pathology report, and on whether monitoring stays a sentence on a website or becomes a scan on a calendar.

Disclaimer: This article is news reporting and analysis of regulator and company statements about Zolgensma, Itvisma, and related AAV programs. It is informational only and is not medical advice, a treatment recommendation, or a diagnosis for any child or adult with spinal muscular atrophy. Families should not start, stop, or change SMA therapy, cancer screening, or follow-up based on this piece; those decisions belong with the treating neurologist or other qualified physician who knows the patient’s history. Counts of tumor reports, integration findings, sales, and product status reflect the FDA, Novartis, SMA Europe, SMA UK, and Cure SMA materials cited here as of the dates on those documents and may change as pathology and the FDA review continue.

Harry is the editor of WORLDHAB, an independent publication that he owns and edits himself. His decade in journalism started in reporting and moved into editing, and it left him with a short list of promises that readers can expect every article here to keep. Sources are named and linked, so a claim about a company, a government or a team can be traced to the statement, filing or transcript it came from. Dates are given in full, figures are checked against the original table before publication, and where a number is an estimate the story says whose estimate it is. Headlines describe what happened rather than tease it. Those expectations hold across all ten sections WORLDHAB publishes for an international audience: news, business, technology and science on one side, sports, entertainment, lifestyle and travel on another, with auto and gaming covered with the same seriousness. Harry keeps a public corrections policy and marks every change on the article it affects. Reader mail is read by him and answered from support@worldhab.com.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending